Sustained stress-induced changes in mice as a model for chronic depression.
BACKGROUND
Major depression is a chronic disabling disorder, often preceded by stress. Despite emerging clinical interest in mechanisms perpetuating episodes of depression and/or establishing increased vulnerability for relapse, little attention has been paid to address these aspects in experimental models. Here, we studied the long-term neuroadaptive effects of chronic mild stress (CMS) as well as the effectiveness of a course of an antidepressant treatment.


METHODS
CMS was applied for 6 weeks, and paroxetine was administered from the third week and continued for 2 weeks thereafter. In order to validate our CMS procedure, we first studied short-term (24 h after CMS) hippocampal cell proliferation and neurogenesis, along with anhedonic-like behaviour. Subsequently, we examined the long-term (one month after CMS) anhedonia, hippocampal neurogenesis, the regulation of c-Fos immunoreactivity and neurotransmitter levels in different areas as well as cortical spine density and hippocampal expression of synaptic proteins.


RESULTS
CMS induced a decrease in short-term neurogenesis that was fully recovered in the long term. In addition, CMS-induced lasting anhedonia and region-specific changes in neuronal activity (c-Fos immunoreactivity) and neurotransmitter (glutamate and GABA) levels. Repeated paroxetine reverted these effects with the exception of decreased neuronal activity in the dentate gyrus (DG) and GABA levels in the ventral hippocampus. Moreover, CMS downregulated the GAD65 and VGLUT1 expressions.


CONCLUSIONS
This study shows region-specific long-term neurobiological adaptations induced by CMS and residual hippocampal signs after paroxetine treatment. We propose the use of this model to study molecular mechanisms involved in chronic depression and vulnerability for relapse.
Elizalde
Natalia
N
Department of Pharmacology, University of Navarra, 31080, Pamplona, Spain.
García-García
Alvaro L
AL
Totterdell
Susan
S
Gendive
Nerea
N
Venzala
Elisabet
E
Ramirez
Maria J
MJ
Del Rio
Joaquin
J
Tordera
Rosa M
RM
D000818:Animals; D049109:Cell Proliferation / Q000187:drug effects; D002908:Chronic Disease; D003865:Major Depressive Disorder / Q000188:drug therapy / Q000523:psychology*; D004195:Disease Models, Animal; D006624:Hippocampus / Q000166:cytology / Q000187:drug effects; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D017374:Paroxetine / Q000494:pharmacology / Q000627:therapeutic use; D013315:Stress, Psychological / Q000188:drug therapy / Q000523:psychology*; D013997:Time Factors
D017374:Paroxetine
Science. 1987 Jul 10;237(4811):192-7
3037702
Am J Psychiatry. 2001 Apr;158(4):582-6
11282692
Neuropsychobiology. 2005;52(2):90-110
16037678
Hippocampus. 2006;16(3):239-49
16425236
Biol Psychiatry. 2003 Nov 15;54(10):1035-40
14625145
Ann N Y Acad Sci. 2008 Dec;1148:86-94
19120094
Bipolar Disord. 2009 Nov;11(7):711-25
19839996
Neuropsychopharmacology. 2006 Nov;31(11):2395-404
16482085
Neuropharmacology. 2008 Mar;54(3):530-41
18164735
Nat Neurosci. 2005 Mar;8(3):365-71
15696163
Neuron. 2009 May 28;62(4):479-93
19477151
Neuropsychopharmacology. 2004 Nov;29(11):2007-17
15266352
Nat Neurosci. 2008 Oct;11(10):1153-61
18758458
J Neurosci. 2000 Dec 15;20(24):9104-10
11124987
Schizophr Res. 2005 Jan 1;72(2-3):109-22
15560956
Behav Brain Res. 2007 Jul 19;181(1):42-51
17477980
J Affect Disord. 2004 Oct 15;82(2):253-8
15488254
Science. 2007 Aug 10;317(5839):819-23
17615305
J Neurosci Methods. 1984 Sep;11(4):221-30
6392756
Mol Psychiatry. 2010 May;15(5):501-11
18825147
Psychol Med. 2008 Mar;38(3):315-8
18298875
Prog Brain Res. 2008;172:233-64
18772036
Trends Neurosci. 2005 Apr;28(4):171-2
15808349
Eur J Neurosci. 2007 Jan;25(1):281-90
17241289
Proc Natl Acad Sci U S A. 1999 Feb 16;96(4):1698-703
9990087
Biol Psychiatry. 2000 Oct 15;48(8):766-77
11063973
Proc Natl Acad Sci U S A. 2003 Feb 4;100(3):1387-92
12552118
J Affect Disord. 2010 Apr;122(1-2):144-8
19692126
Mol Psychiatry. 2004 Mar;9(3):278-86, 224
14699428
J Neurosci. 2007 Mar 21;27(12):3252-9
17376985
Neuropsychopharmacology. 2009 Apr;34(5):1263-76
18923397
J Abnorm Psychol. 2008 Feb;117(1):206-13
18266498
Eur J Neurosci. 2000 Jan;12(1):391-6
10651896
Am J Psychiatry. 2007 Mar;164(3):516-9
17329478
Biol Psychiatry. 2005 Apr 15;57(8):935-7
15820716
Brain Res. 2000 May 19;865(1):45-58
10814732
Biol Psychiatry. 2009 Aug 1;66(3):275-82
19409534
CNS Neurol Disord Drug Targets. 2006 Oct;5(5):531-46
17073656
Biol Psychiatry. 2003 Nov 15;54(10):1025-34
14625144
Arch Gen Psychiatry. 2004 Jul;61(7):705-13
15237082
Psychol Med. 2008 Mar;38(3):307-13
18444278
J Clin Psychiatry. 2004;65 Suppl 17:29-33
15600379
Psychiatry Res. 2004 Dec 15;132(2):141-7
15598548
Mol Psychiatry. 2003 Aug;8(8):721-37, 715
12888801
Behav Pharmacol. 2006 May;17(3):271-87
16572005
Stress. 2010 Mar;13(2):95-105
19929309
Neurosci Biobehav Rev. 2004 May;28(3):273-83
15225971
Psychopharmacology (Berl). 2008 Jul;199(1):1-14
18470507
Am J Psychiatry. 1992 Aug;149(8):999-1010
1353322
Hippocampus. 2009 Dec;19(12):1222-31
19309038
BMC Neurosci. 2007 Dec 19;8:107
18093285
Am J Psychiatry. 2000 Sep;157(9):1501-4
10964869
Annu Rev Clin Psychol. 2005;1:293-319
17716090
Eur Arch Psychiatry Clin Neurosci. 2007 Aug;257(5):250-60
17401728
Science. 2003 Aug 8;301(5634):805-9
12907793
Am J Psychiatry. 2000 Feb;157(2):229-33
10671391
Neuroscience. 2007 Dec 5;150(2):251-9
17981399
Arch Gen Psychiatry. 2008 Oct;65(10):1156-65
18838632
Mol Psychiatry. 2006 May;11(5):514-22
16415915
Hippocampus. 1998;8(6):608-19
9882018
Int J Neuropsychopharmacol. 2008 Mar;11(2):255-60
17625025
Neurosci Bull. 2007 May;23(3):131-6
17612590
Mol Psychiatry. 2009 Aug;14(8):764-73, 739
18982002